Hamilton Bancorp, Inc. Reports Results for the Fourth Quarter and Fiscal Year Ended March 31, 2015

Towson, Md. (PRWEB) May 28, 2015

Hamilton Bancorp, Inc. (the “Company”) (NASDAQ: HBK), the parent company of Hamilton Bank (the “Bank”), today announced a $ 0.13 improvement in net loss per share for the fourth quarter of 2015. The Company recorded a net loss of $ 141,000 or $ 0.04 per share for the quarter ended March 31, 2015, compared to a net loss of $ 566,000 or $ 0.17 per share for the same quarter a year ago. The results for 2015 include non-recurring merger related expenses of $ 74,000.

“There is a lot of excitement in and around the projected growth plan and achievements of the Hamilton Bank team. Between the recently announced merger with Fairmount Bancorp, Inc., improving core earnings, and the decrease in our non-performing assets, our extended team is working together to move our business metrics in the right direction,” said President and CEO Bob DeAlmeida. “This year is particularly exciting as we celebrate our 100-year anniversary. Many stakeholders have participated in helping us mark this terrific milestone.”

Additional company highlights for the three-month period and fiscal year ended March 31, 2015, include:


    During the fourth quarter of fiscal 2015, the Company was in discussions with, and performed due diligence on, Fairmount Bancorp, Inc. (“Fairmount”), and subsequent to the fiscal year end, in April 2015 announced the signing of a definitive agreement with Fairmount. A large portion of the loss for the quarter is attributable to the costs incurred to perform the due diligence and draft a definitive agreement outlining the merger.
    Nonperforming assets to total assets decreased more than 50 percent during fiscal 2015 from 1.88 percent at March 31, 2014 to 0.93 percent at March 31, 2015.
    Net charge-offs declined $ 1.9 million, or 88 percent, during fiscal 2015 to $ 266,000, or 0.18 percent of average loans, from $ 2.2 million, or 1.41 percent, of average loans for fiscal 2014. This decrease resulted in reduced provisions for loan losses of $ 170,000 for fiscal 2015 compared to $ 1.9 million for fiscal 2014.
    Net loss attributable to common shareholders decreased to $ 314,000 for the fiscal year ended March 31, 2015, compared to a net loss of $ 1.2 million for fiscal 2014, an improvement of $ 881,000. Net loss per common share improved to $ 0.10 for the year compared to $ 0.35 in the prior fiscal year. This improvement was associated with a $ 1.7 million decrease in the provision for loan loss; a reflection of the continued decrease in charge-offs and problem loans.
    Net interest margin for the fourth quarter of fiscal 2015 increased 10 basis points to 2.98 percent compared to 2.88 percent for the same period last year due to an increase in the average balance of higher interest-earning assets, primarily commercial loans.
    Total gross loans, including loans held for sale, increased $ 16.2 million, or 11.2 percent, during fiscal 2015, from $ 144.8 million at March 31, 2014 to $ 161.0 million at March 31, 2015. Roughly $ 11.7 million, or 73 percent, of that growth occurred in the second half of fiscal 2015 as the Bank continued to show growing strength in its commercial lending platform.

“Understanding the ‘why’ is an important perspective when evaluating Hamilton’s performance over time,” said Executive Vice President – Chief Lending Officer Ellen Fish. “Our daily, unwavering commitment to secure sound commercial lending, obtain lower cost core deposits, and embrace overall asset quality remains firm. I am very optimistic about our future as our team works tirelessly to deliver for our shareholders.”

During the fiscal year ending March 31, 2015, commercial real estate loans grew $ 17.9 million, or 43.1 percent, to $ 59.3 million, while commercial business loans also grew by $ 2.8 million, or 18.1 percent, to $ 18.5 million over the same period. Approximately $ 12.8 million of the growth in commercial real estate occurred in the last two quarters of fiscal 2015.

The Bank’s asset quality measures continue to improve. Nonperforming loans decreased $ 2.8 million, or 55.3 percent, to $ 2.3 million at March 31, 2015 from $ 5.0 million a year ago. Nonperforming loans as a percentage of gross loans decreased from 3.48 percent at March 31, 2014 to 1.40 percent at March 31, 2015.

The Bank continued to allow higher cost certificates of deposit to run-off and to focus on generating lower cost core deposits (which is considered to be all deposits except certificates of deposit), including checking and money market accounts. Total deposits were $ 222.3 million at March 31, 2015, compared to $ 238.8 million at March 31, 2014, a decline of $ 16.5 million, or 6.9 percent. Core deposits increased by $ 3.9 million, or 5.7 percent, to $ 72.6 million over the twelve months of fiscal 2015 while certificates of deposit decreased $ 20.4 million over that same period. Core deposits comprised 32.7 percent of total deposits at March 31, 2015 compared to 28.8 percent at March 31, 2014.

For fiscal 2015, the Company reported net interest income of $ 7.7 million compared to $ 8.3 million for fiscal 2014. The decrease in net interest income over that period is due to an $ 847,000 decrease in interest revenue that is attributable to a $ 6.3 million decline in average loan balances and a 28 basis point decline in loan yield. However, during the second half of fiscal 2015, the Company saw overall loan balances grow under its restructured commercial lending platform and enhanced interest revenue despite a low interest rate environment. Partially offsetting the decline in interest revenue is a $ 254,000 decrease in interest expense, resulting from an $ 18.4 million decrease in the average balance of higher cost certificates of deposit during fiscal 2015. The Company’s net interest margin for fiscal 2015 remained unchanged at 2.85 percent compared to fiscal 2014.

Noninterest revenue for fiscal 2015 increased by $ 30,000, or 2.9 percent, to $ 1.1 million compared to the same period last year that included an $ 82,000 gain on the sale of the Bank’s Belmar branch. A large portion of this increase is due to $ 272,000 in gains realized from the sale of investment securities compared to $ 172,000 in realized gains for the same period a year ago. Fee income from service charges also improved by $ 17,000 from $ 366,000 in fiscal 2014 to $ 383,000 in fiscal 2015.

Noninterest expense decreased to $ 9.3 million for fiscal 2015 compared to $ 9.7 million for fiscal 2014, a decrease of $ 395,000. Despite salaries and benefits increasing $ 424,000 over that period due to new lending personnel and cost associated with equity awards, the Bank was able to offset this increase by reducing other noninterest expenses, particularly legal fees and other professional services. These expenses decreased, as a whole, by $ 269,000 due to a reduction in problem assets and the cost associated with implementing the Bank’s equity incentive plans. In addition, occupancy and advertising expenses also decreased by $ 131,000 and $ 109,000, respectively, over the fiscal year compared to fiscal 2014, as management diligently looked for ways to cut costs and improve efficiency moving forward. Lastly, foreclosed real estate expense and losses decreased significantly due to $ 493,000 in costs incurred in the prior year associated with the sale of one property and the write-down of another held in foreclosed real estate.

When comparing the third and fourth quarter of fiscal 2015, net income of $ 78,000 was recorded in the third quarter compared to a net loss of $ 141,000 in the fourth quarter. The net income per share decreased from a profitable $ 0.02 per share in the prior quarter to a loss of $ 0.04 per share in the most recent quarter. The loss for the current quarter is attributable to a $ 221,000 write-down in the fair value of a property held in foreclosed real estate and $ 74,000 in costs incurred relating to the due diligence work performed and signing of a definitive agreement to merge with Fairmount. These costs were partially offset by a $ 175,000 negative provision for loan losses taken in the fourth quarter. The Company has been able to record a negative provision in the last two quarters due to the reduction in its problem assets and improved asset quality. In addition, loan volume continues to show strength from quarter to quarter. The loan portfolio increased from $ 159.0 million at December 31, 2014 to $ 160.9 million at March 31, 2015, an increase of $ 1.9 million following net loan growth of $ 9.7 million in the prior fiscal quarter.

Average equity to average assets remains strong at 19.8 percent for the fourth quarter ended March 31, 2015, down slightly from 20.6 percent a year ago as a result of stock buybacks, partially offset by a decrease in the average asset base. All of the Bank’s regulatory capital ratios continue to exceed those levels required for the Bank to be categorized as well capitalized. The Company’s shares outstanding decreased from 3,595,100 at March 31, 2014 to 3,417,713 shares at March 31, 2015. This reduction is due to a 5 percent buyback of common shares in the first quarter of fiscal 2015.

Please direct all media inquiries to Josie Hankey at 410-420-2001 or by email at josie(dot)hankey(at)fallstongroup(dot)com. Please direct investor inquiries for Hamilton Bank to Robert DeAlmeida at 410-823-4510.

About Hamilton Bank

Founded in 1915, Hamilton Bank is a community bank with $ 285 million in assets and $ 46.9 million in regulatory capital. The bank employs more than 55 people and operates four branch locations across Greater Baltimore, serving the communities of Cockeysville, Pasadena, Towson and Baltimore in Maryland. Whether online or on the corner, Hamilton Bank is a community bank that cares about its customers. http://www.Hamilton-Bank.com.

Member FDIC and Equal Housing Lender

This press release may contain statements relating to the future results of the Company (including certain projections and business trends) that are considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995). Forward-looking statements include statements regarding anticipated future events and can be identified by the fact that they do not relate strictly to historical or current facts. They often include words such as “believe,” “expect,” “anticipate,” “estimate,” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.” Forward-looking statements, by their nature, are subject to risks and uncertainties. Certain factors that could cause actual results to differ materially from expected results include increased competitive pressures, changes in the interest rate environment, general economic conditions or conditions within the securities markets, legislative and regulatory changes that could adversely affect the business in which Hamilton Bancorp, Inc. and Hamilton Bank are engaged, and other factors that may be described in the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this release, and, except as may be required by applicable law or regulation, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements.







More Legal Press Releases

DePuy ASR Lawsuit News: Federal Court Extends Deadline on Tolling Agreements for Non-Revision Plaintiffs, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) December 28, 2014

The federal court overseeing thousands of DePuy ASR hip lawsuits (http://www.consumerinjurylawyers.com/DePuy/) has extended the deadline by which non-revision plaintiffs must decide to enter into a tolling agreement with Johnson & Johnson and its DePuy Orthopaedics unit, Bernstein Liebhard LLP reports. According to an Order posted December 24th on the website for the U.S. District Court, Northern District Ohio, such plaintiffs must now notify the Court by January 31, 2015 if they intend to continue with their case or voluntarily dismiss their lawsuit. Per an earlier court Order, plaintiffs who opt for voluntarily dismissal would enter into a tolling agreement with the defendants that would call for the refiling of their claim should they require revision of their ASR hip implant in the future.* (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – MDL 2197)

“We are representing numerous plaintiffs who have filed lawsuits in this proceeding. As non-revision plaintiffs are not eligible to participate in the settlement program announced last year, entering into a tolling agreement may be a viable option for these individuals,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices.

The Firm continues to offer free legal evaluations to individuals who allegedly experienced metallosis, chronic pain, disability, premature hip implant failure, and other serious complications allegedly related to devices included in the DePuy ASR recall.

DePuy ASR Litigation

According to court documents, the DePuy ASR hip recall was announced in August 2010, after data indicated that the metal-on-metal hips were failing at an unacceptably high rate within just five years of implantation. Since then, thousands of product liability claims have been filed in state and federal courts on behalf of individuals who allegedly suffered serious complications due to their ASR hips, most of which have been consolidated in a multidistrict litigation established in the Northern District of Ohio.

Last November, the Court announced the establishment of the DePuy ASR settlement program, which could ultimately resolve the majority of cases pending in state and federal courts. However, those eligible to participate in the program were limited to DePuy ASR recipients who underwent revision surgery to replace their implant due to a recall-related reason prior to August 31, 2013.

Individuals who allegedly suffered serious complications related to the DePuy ASR recall may be entitled to compensation for their injury-related damages. To learn more about the DePuy ASR litigation, please visit Bernstein Liebhard LLP’s website. For a free, no obligation case review, please call the Firm directly at 800-511-5092.

*ohnd.uscourts.gov/assets/CMO-24A.pdf, U.S. District Court, Northern District of Ohio, December 24, 2014

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.consumerinjurylawyers.com

https://plus.google.com/115936073311125306742?rel=author







Vaginal Mesh Lawsuit News: Boston Scientific Loses Bid for Summary Judgment on Negligence, Warning Claims in Federal Obtryx Case, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) October 23, 2014

The federal judge overseeing thousands of vaginal mesh lawsuits (http://www.consumerinjurylawyers.com/transvaginal-mesh-recall-lawsuit.html) filed against Boston Scientific Corp. has denied the company’s Motion for Summary Judgment on negligence and warning claims put forth in one case involving the Obtryx Transobturator Mid-Urethral Sling System. The lawsuit, which is currently pending in the federal multidistrict litigation now underway in the U.S. District Court, Southern District of West Virginia, claims that the Obtryx device caused the plaintiff to suffer erosion, mesh contraction, infection, fistula, inflammation, scar tissue, organ perforation, and other serious vaginal mesh complications. According to an Order issued on October 17th, Judge Joseph R. Goodwin allowed her failure to warn, negligence and breach of warranty claims to go forward after finding that the lawsuit had established issues of fact as to the safety and effectiveness of the device. (Tyree, et al. v. Boston Scientific Corp., No. 2:12-8633)

According to court documents, this lawsuit is one of four Boston Scientific cases involving Obtryx mesh that have been consolidated for the proceeding’s first bellwether trial. That trial is scheduled to begin on November 3, 2014.

“Our Firm is closely monitoring the progress of vaginal mesh lawsuits filed against Boston Scientific Corp. and other companies, as we are representing hundreds of women in claims that put forth similar allegations,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free legal reviews to women who suffered mesh erosion, pain, scarring, infection and other serious transvaginal mesh complications, allegedly due to products marketed by a number of manufacturers.

Transvaginal Mesh Litigation

Court records indicate that Boston Scientific has been named a defendant in more than 14,000 vaginal mesh lawsuits that are currently pending in the Southern District of West Virginia. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving as a member of the Plaintiffs’ Steering Committee for this proceeding. All the claims filed in this litigation similarly allege that pelvic mesh products marketed by Boston Scientific were defectively designed and manufactured, and caused women to suffer a wide variety of painful and debilitating transvaginal mesh complications. (In re: Boston Scientific Corp., Pelvic Repair Systems Products Liability Litigation – MDL No. 2326)

Court records indicate that more than 60,000 transvaginal mesh lawsuits are currently pending in several litigations underway in the Southern District of West Virginia. Mr. Grand isalso a member of the Plaintiffs’ Steering Committee for other federal proceedings, including those involving American Medical Systems, Inc. (MDL No. 2325), C.R. Bard, Inc. (MDL 2326) and Ethicon, Inc. (MDL No. 2327).

Mr. Grand was also appointed Co-Liaison Counsel in two multicounty litigations established for C.R. Bard and Ethicon mesh lawsuits in New Jersey’s Atlantic Superior Court. He was also a member of the trial team on the first Ethicon trial, which ended in March 2013 with an $ 11 million verdict for the Plaintiff. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)

Women who were allegedly harmed by pelvic mesh products used to treat pelvic organ prolapse or stress urinary incontinence may be entitled to pursue a legal claim against the manufacturer of the device. To learn more about filing a vaginal mesh lawsuit, please visit Bernstein Liebhard LLP’s website or the firm’s Facebook page: https://www.facebook.com/meshlawsuit. To arrange for a free legal consultation, please call 800-511-5092

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.consumerinjurylawyers.com

https://plus.google.com/115936073311125306742?rel=author







Find More Legal Press Releases

Xarelto Lawsuit News: New Study Says Treatment Strategies For Venous Thromboembolisms Have Bleeding Risks Reports Wright & Schulte LLC

Columbus, OH (PRWEB) October 12, 2014

Wright & Schulte LLC reports a recently released study found that most treatment options for blood clots in veins (venous thromboembolisms) are equally safe and effective yet major bleeding occurred in patients using the anticoagulants including Xarelto. The research, published in the September 17, 2014 issue of the Journal of the American Medical Association, examined eight different anticoagulant drugs, including unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), combined with vitamin K antagonists, which are also anticoagulants. Researchers from the University of Ottawa, Ontario, Canada, also included 45 randomized trials, which had a total number of 44,989 patients in their analyses. The study found nearly half of a percentage (0.49 percent) of patients had a major bleeding event during three months of treatment with Xarelto (rivaroxaban), and 0.29 percent had a major bleeding episode with Eliquis. The study’s authors concluded that, except for the UFH-vitamin K antagonist combination, all other treatment strategies had bleeding risks similar to the LMWH-vitamin K antagonist combination. As studies continue on the effectiveness of anticoagulants such as Xarelto, court records indicate that Xarelto lawsuits allege that major bleeding events are side-effects of taking the Xarelto blood thinner and there is no antidote to reverse the uncontrolled bleeding, one of which was filed the U.S. District Court, Eastern District of New York (Case No. 1:14-cv-04841-FB-VMS)

[media.jamanetwork.com/news-item/study-compares-effectiveness-of-treatments-for-blood-clots/, September 16, 2014.]

The attorneys at Wright & Schulte continue to investigate claims of uncontrolled bleeding due to Xarelto and offer free legal claims to men and women who believe they have experienced bleeding side-effects from Xarelto and other anticoagulant drugs by calling 1-800-399-0795 or by visiting http://www.yourlegalhelp.com for information on this and other medication news.

Xarelto is a new-generation oral blood thinner first approved by the U.S. Food & Drug Administration (FDA) in July 2011 to reduce deep vein thrombosis and pulmonary embolism in patients who had knee or hip replacement surgery. In November 2011, FDA expanded approval for Xarelto to treat deep being thrombosis. In November 2012, Xarelto was approved to treat and prevent recurrence of deep vein thrombosis and pulmonary embolism and to reduce the risk of the conditions recurring following initial treatment. Unlike warfarin (Coumadin, Jantoven), a blood thinner approved by the FDA in 1954, Xarelto does not have a specific reversal agent should significant bleeding occur. Vitamin K is used as the antidote for patients taking warfarin.

[fda.gov/newsevents/newsroom/pressannouncements/ucm326654.htm, November 2, 2012]

[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

Court documents indicate that Xarelto lawsuits are being filed in courts throughout the United States, including a wrongful death lawsuit filed on August 14, 2014, in the U.S. District Court, Eastern District of New York on behalf of a 92-year-old Tennessee man. (Case No. 1:14-cv-04841-FB-VMS) According to the Xarelto complaint, the Tennessee man first began using the blood thinner medication from May 2013 and continued to use until August 2013. The Xarelto lawsuit alleges that due to using Xarelto, the man suffered life-threatening bleeding on August 25, 2013, and sustained severe and permanent personal injuries, pain, suffering and emotional distress. The man died on December 6, 2013. The Xarelto complaint purports that defendants Jannssen Pharmaceuticals and Bayer failed to warn emergency room doctors and other medical professionals as well as disclose to patients that there is no effective agent to reverse the anticoagulation effects of Xarelto, and therefore there is no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Xarelto.

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free low testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







Find More Law Press Releases

Hastings And Hastings Reports Success With Its Mobile Website

PHOENIX, AZ (PRWEB) July 04, 2014

Hastings and Hastings, a personal injury attorney group in metropolitan Phoenix, Arizona reports success with its mobile website that offers quick and easy access to a wide range of legal services via mobile devices. As a discount law firm that continues to strive to exceed client’s expectations with regard to the latest in website access, Hastings and Hastings has been providing the residents of Phoenix and the state of Arizona with highly experienced attorneys as well as a specialist certified by the Arizona State Bar as a legal professional specifically focused on injury and wrongful death litigation. With nearly 150 years of combined legal experience, the attorneys of Hastings and Hastings have effectively resolved injury cases that number in the tens of thousands.

Many residents throughout Phoenix have relied upon Hastings and Hastings when experiencing a devastating or catastrophic event that is typically life changing. From wrongful death cases that are the result of someone else’s negligence to automobile accidents, motorcycle accidents and truck accidents as well as pedestrian and bicycle accidents, Hastings and Hastings helps to effectively resolve personal injury cases for accident victims each and every day. When accident victims must retain counsel as soon as possible as a way to protect the integrity of an investigation of any claims, they routinely rely upon a law firm that offers substantial discounts. This professional personal injury law firm handles all the calls from attorneys and insurance companies of the negligent party. This allows clients to continue on with their normal daily life and routine.

Other areas of Phoenix personal injury law that Hastings and Hastings handles include everything from dog bite related accidents resulting in injuries to slip and fall accidents as well as wrongful death cases and any other type of accident that may have been the result of another person’s or company’s negligence. As a highly focused discount accident law firm, Hastings and Hastings also handles property damage cases and other injury related cases. A Phoenix discount accident lawyer that has been helping accident victims for decades and offers deep discounts is always close at hand for the residents of Arizona when they contact Hastings and Hastings.

In addition, over the last several years, Hastings and Hastings has effectively saved injured clients well over $ 11 million dollars in attorneys fees thanks to a strict adherence to a deeply discounted fee schedule. The success of its innovative mobile website design further serves to simplify the process of retaining a lawyer for anyone that have been injured in an accident. With a strong focus on all aspects of personal injury, Hastings And Hastings understands the importance of timely and accurate filing of a settlement claim. This recent report with regard to the success of the firm’s mobile website that is optimized for easier and faster access by clients and potential clients is one more indication that Hastings and Hastings continues to make personal injury legal assistance more accessible and more affordable to more people than ever before.

Hastings and Hastings is a leading provider of discount personal injury legal services located in and serving the greater Phoenix Metropolitan area. This respected legal firm specializes in assisting individuals that have been the victim of accidents that result in serious injuries resulting from accidents that were not fault of their own. Hastings and Hastings is a trusted and dependable group of attorneys that delivers personalized service and guidance for injury victims throughout Phoenix and all across the state of Arizona. Hastings and Hastings is known throughout legal circles as a dedicated team of professionals and a law firm that has been representing accident victims throughout Arizona for decades. The firm consistently exceeds client’s expectations with regard to representing a wide array of accident injury cases at times when it matters the most while always doing so with a noticeable discount.







Related Accident Press Releases